Autopsy report · NCT01549392

Imaging Study of Glioblastomas Treated With Avastin

“insufficient accrual”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 1 month before it stopped.
• 3 participants enrolled.
• Results were posted on the registry 6 months after it ended.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

London Health Sciences Centre

Sponsor type

University, hospital or other

Conditions

Malignant Gliomas

Interventions

DECT; MR spectroscopy

Participants

3

Sites

1

Countries

Canada

Trials that died the same way

• TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC)
  “failure to accrue” (89% match in meaning)
• Pressure Enabled Drug Delivery By Pancreatic Retrograde Venous Infusion For Advanced Pancreatic Carcinoma
  “Insufficient accrual rate” (85% match in meaning)
• Effect of Metformin on Biomarkers of Colorectal Tumor Cell Growth
  “Inadequate accrual” (84% match in meaning)
• Pharmacology of Aminophylline for Acute Kidney Injury in Neonates
  “insufficient rate of accrual” (83% match in meaning)
• A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms
  “unable to accrue” (83% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.